Deaths Attributable to Cancer in the US Human Immunodeficiency Virus Population During 2001–2015

Marie-Josèphe Horner & Eric A Engels et al.

Abstract

Background

Antiretroviral therapy (ART) has reduced mortality among people living with human immunodeficiency virus (HIV), but cancer remains an important cause of death. We characterized cancer-attributable mortality in the HIV population during 2001–2015.

Methods

We used data from population-based HIV and cancer registries in the United States (US). Cox proportional hazards regression models were used to estimate adjusted hazard ratios (HRs) associating cancer diagnoses with overall mortality. Population-attributable fractions (PAFs) were calculated using these HRs and the proportion of deaths preceded by cancer. Cancer-specific PAFs and cancer-attributable mortality rates were calculated for demographic subgroups, AIDS-defining cancers (Kaposi sarcoma [KS], non-Hodgkin lymphoma [NHL], cervical cancer), and non–AIDS-defining cancers.

Results

Cancer-attributable mortality was 386.9 per 100 000 person-years, with 9.2% and 5.0% of deaths attributed to non–AIDS-defining and AIDS-defining cancers, respectively. Leading cancer-attributable deaths were from NHL (3.5%), lung cancer (2.4%), KS (1.3%), liver cancer (1.1%), and anal cancer (0.6%). Overall, cancer-attributable mortality declined from 484.0 per 100 000 person-years during 2001–2005 to 313.6 per 100 000 person-years during 2011–2015, while the PAF increased from 12.6% to 17.1%; the PAF for non–AIDS-defining cancers increased from 7.2% to 11.8% during 2011–2015. Cancer-attributable mortality was highest among those aged ≥60 years (952.2 per 100 000 person-years), with 19.0% of deaths attributed to non–AIDS-defining cancers.

Conclusions

Although cancer-attributable mortality has declined over time, it remains high and represents a growing fraction of deaths in the US HIV population. Mortality from non–AIDS-defining cancers may rise as the HIV population ages. ART access, early cancer detection, and improved cancer treatment are priorities for reducing cancer-attributable mortality.

Authors
Marie-Josèphe Horner, Meredith S Shiels, Ruth M Pfeiffer, Eric A Engels
Funding
NCCDPHP CDC HHS Grant NU58DP006344GEORGIA COMPREHENSIVE CANCER CONTROL PROGRAMNCCDPHP CDC HHS Grant NU58DP006344NEW YORK STATE CANCER PREVENTION & CONTROL PROGRAMNCI NIH HHS Grant HHSN261201300019INCI NIH HHS Grant HHSN261201200021IHIV/AIDS SURVEILLANCECore and Incidence Surveillance for HIV in MichiganNational HIV Surveillance SystemNational Cancer Institute Grant HHSN261201300019INational Cancer Institute Grant HHSN261201300021INational Cancer Institute Grant N01-PC-2013-00021National Institutes of Health FundingCenters for Disease Control and Prevention Grant NU58DP006347-01GEORGIA COMPREHENSIVE CANCER CONTROL PROGRAMCenters for Disease Control and Prevention Grant 17NU58DP006334Centers for Disease Control and Prevention Grant NU58/DP003931-05-00Centers for Disease Control and Prevention Grant U58/DP003879Centers for Disease Control and Prevention Grant 1NU58DP006281Centers for Disease Control and Prevention Grant 1NU58DP006308Centers for Disease Control and Prevention Grant DP006302Centers for Disease Control and Prevention Grant NU62PS003960HIV/AIDS SURVEILLANCECore and Incidence Surveillance for HIV in MichiganCenters for Disease Control and Prevention Grant U62PS004001-2Centers for Disease Control and Prevention Grant NU62PS924546-02-00

NCCDPHP CDC HHS

U58 DP003875

NCCDPHP CDC HHS

U58 DP003879

NCHHSTP CDC HHS

U62 PS001005

NCHHSTP CDC HHS

U62 PS004011

NCHHSTP CDC HHS

U62 PS004001

Centers for Disease Control and Prevention

5U58DP003875-01

Centers for Disease Control and Prevention

5U62PS001005-05

Centers for Disease Control and Prevention

U62PS004011-02